MBRX
Moleculin Biotech·NASDAQ
--
--(--)
--
--(--)
4.63 / 10
Netural
Fund-flow metrics are encouraging (7.43/10), with small-cap and extra-large inflows trending positively, offsetting negative signals in overall, block, and medium/large flows. Analyst coverage is minimal (only one opinion, Strong Buy), but the historical win-rate is low (33.3%), tempering conviction. Sentiment remains neutral overall.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-12-11
InstitutionHC Wainwright & Co.
Times predicted3
Historical Win Rate33.3%
Is money flowing into or out of MBRX?
- MBRX holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 4.63/10 (Netural).
